These are links to recent news stories that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter.
Ocrelizumab for progressive MS trail results
Genentech have announced positive results from a phase III study of ocrelizumab in primary progressive MS. The ORATORIO trial was looking for reductions in progression, as measured by EDSS, sustained for 12 weeks. Little detail in the press release, but top line results will be presented at the ECTRIMS conference in October.
MS Trust link: Ocrelizumab